company background image
PHG logo

Pharming Group DB:PHG Stock Report

Last Price

€8.35

Market Cap

€597.3m

7D

3.1%

1Y

-17.3%

Updated

23 Dec, 2024

Data

Company Financials +

PHG Stock Overview

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details

PHG fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Pharming Group N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharming Group
Historical stock prices
Current Share Price€8.35
52 Week High€11.70
52 Week Low€6.00
Beta0.80
1 Month Change21.01%
3 Month Change25.56%
1 Year Change-17.33%
3 Year Change12.84%
5 Year Changen/a
Change since IPO-26.54%

Recent News & Updates

Recent updates

Shareholder Returns

PHGDE BiotechsDE Market
7D3.1%-3.5%-2.0%
1Y-17.3%-14.7%6.9%

Return vs Industry: PHG underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: PHG underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is PHG's price volatile compared to industry and market?
PHG volatility
PHG Average Weekly Movement7.3%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PHG's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: PHG's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1988382Simon de Vrieswww.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHG fundamental statistics
Market cap€597.29m
Earnings (TTM)-€17.08m
Revenue (TTM)€273.86m

2.2x

P/S Ratio

-35.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHG income statement (TTM)
RevenueUS$285.75m
Cost of RevenueUS$30.30m
Gross ProfitUS$255.44m
Other ExpensesUS$273.26m
Earnings-US$17.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.026
Gross Margin89.39%
Net Profit Margin-6.24%
Debt/Equity Ratio42.3%

How did PHG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Joseph PantginisH.C. Wainwright & Co.